Table 2. Candidate interventions excluded during short-listing.
| Drug | Reason for exclusion |
|---|---|
| 15+- Dexoxyspergualin | Immunosuppressive MOA |
| 4 Ammonium Phosphate | Limited biological plausibility |
| Adrenocorticotropic Hormone | Immunosuppressive MOA |
| Adrenocorticotropic Hormone 1–17 | Immunosuppressive MOA |
| Amantidine/Isoprinosine | Symptomatic benefit |
| Anastal | Combination therapy |
| Antithymocyte Globulin | Immunosuppressive MOA |
| Arachidonic Acid | Limited biological plausibility |
| Azathioprine | Immunosuppressive MOA |
| Azathioprine & Prednisolone | Immunosuppressive MOA |
| Azathioprine/6-mercaptopurine | Immunosuppressive MOA |
| Baclofen | Symptomatic benefit |
| BHT-3009 | Parenteral administration |
| Cannabidiol/Tetrahydrocannabinol | Previously tested |
| Cannabis extract | Previously tested |
| Cannabis Oil | Previously tested |
| Chlorambucil | Immunosuppressive MOA |
| Cladribine | Immunosuppressive MOA |
| Cladrybine | Immunosuppressive MOA |
| Clofibrate | Withdrawn from market |
| Cranberry Juice | Symptomatic benefit |
| Cyclophosphamide | Immunosuppressive MOA |
| Cyclophosphamide/predisone | Immunosuppressive MOA |
| Cyclosporine A | Immunosuppressive MOA |
| D-penicillamine&Metacycline | Immunosuppressive MOA |
| D1 | Limited biological plausibility |
| Dantrolene Sodium | Symptomatic benefit |
| delta-9-tetrahydrocannabinol | Previously tested |
| Desmopressin | Symptomatic benefit |
| Di Huang Cong Ji | Limited biological plausibility |
| Donepezil | Symptomatic benefit |
| DS103-282 | Symptomatic benefit |
| Efamol | Combination therapy |
| Estrogen | Adverse safety profile |
| Fatty Acids | Combination therapy |
| Fumarate (BG00012) | In commercial development |
| IFN-beta 1b | Immunosuppressive MOA |
| Indoramin | Symptomatic benefit |
| Isoprinosine | Limited biological plausibility |
| Lamotrigine | Previously tested |
| Laquinomod | In commercial development |
| Lycopid | Limited biological plausibility |
| Methotrexate | Immunosuppressive MOA |
| Mitoxantrone | Immunosuppressive MOA |
| Mizoribine | Immunosuppressive MOA |
| MK-677 | Symptomatic benefit |
| MMF (Mycophenolate-mofentil) | Immunosuppressive MOA |
| MS14 | Limited biological plausibility |
| Oxybutynin | Symptomatic benefit |
| Padma 28 | Limited biological plausibility |
| Paroxetine | In class with better data |
| Piracetam/Cinnarizine | Symptomatic benefit |
| Prednisolone | Immunosuppressive MOA |
| Prednisolone/Levamisole | Immunosuppressive MOA |
| Prucalopride | Symptomatic benefit |
| Pyrogenalum/Flower Pollen/Colstrum | Limited biological plausibility |
| Rivastigmine | Symptomatic benefit |
| Rutagraveolens | Limited biological plausibility |
| Sulfasalazine | Immunosuppressive MOA |
| Tacrine | Previously tested |
| Tetrahydrocannabinol | Previously tested |
| Tizanidine | Symptomatic benefit |
| Tolperisone | Symptomatic benefit |
| Tolterodine | Symptomatic benefit |
| Triamcinolon | Immunosuppressive MOA |
| TripterygiumWilpordii | Limited biological plausibility |
| Vigabatrin | Adverse safety profile |
| Vitamin D/Calcium/Magnesium | Combination therapy |
MOA = mechanism of action